
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
“There's going to be a whole slew of interesting therapies that are about to emerge for prostate cancer, adds Ketan K. Badani, MD, in this video. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.

